1. Home
  2. CEPO vs NMRA Comparison

CEPO vs NMRA Comparison

Compare CEPO & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CEPO
  • NMRA
  • Stock Information
  • Founded
  • CEPO 2020
  • NMRA 2019
  • Country
  • CEPO United States
  • NMRA United States
  • Employees
  • CEPO N/A
  • NMRA N/A
  • Industry
  • CEPO
  • NMRA
  • Sector
  • CEPO
  • NMRA
  • Exchange
  • CEPO NYSE
  • NMRA Nasdaq
  • Market Cap
  • CEPO 259.6M
  • NMRA 287.6M
  • IPO Year
  • CEPO 2025
  • NMRA 2023
  • Fundamental
  • Price
  • CEPO $10.35
  • NMRA $0.65
  • Analyst Decision
  • CEPO
  • NMRA Buy
  • Analyst Count
  • CEPO 0
  • NMRA 8
  • Target Price
  • CEPO N/A
  • NMRA $9.29
  • AVG Volume (30 Days)
  • CEPO 53.8K
  • NMRA 1.2M
  • Earning Date
  • CEPO 01-01-0001
  • NMRA 05-06-2025
  • Dividend Yield
  • CEPO N/A
  • NMRA N/A
  • EPS Growth
  • CEPO N/A
  • NMRA N/A
  • EPS
  • CEPO N/A
  • NMRA N/A
  • Revenue
  • CEPO N/A
  • NMRA N/A
  • Revenue This Year
  • CEPO N/A
  • NMRA N/A
  • Revenue Next Year
  • CEPO N/A
  • NMRA N/A
  • P/E Ratio
  • CEPO N/A
  • NMRA N/A
  • Revenue Growth
  • CEPO N/A
  • NMRA N/A
  • 52 Week Low
  • CEPO $10.04
  • NMRA $0.62
  • 52 Week High
  • CEPO $10.62
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • CEPO N/A
  • NMRA 22.34
  • Support Level
  • CEPO N/A
  • NMRA $0.64
  • Resistance Level
  • CEPO N/A
  • NMRA $0.83
  • Average True Range (ATR)
  • CEPO 0.00
  • NMRA 0.09
  • MACD
  • CEPO 0.00
  • NMRA 0.02
  • Stochastic Oscillator
  • CEPO 0.00
  • NMRA 6.68

About CEPO CANTOR EQUITY PARTNERS I INC

Cantor Equity Partners I Inc is a blank check company.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Share on Social Networks: